2022-07-20-世界卫生组织-INN_Proposed_List_127_290页_4mb

报告摘要

Summary of International Nonproprietary Names for Pharmaceutical Substances (INN)

Core Content

The document outlines the International Nonproprietary Names (INN) for pharmaceutical substances, focusing on the Proposed INN List 127. These names are under consideration by the World Health Organization (WHO) for inclusion in the Cumulative List of INNs No. 17, 2017, which is only available in CD-ROM format. It emphasizes that the inclusion of a name in the proposed list does not imply any recommendation for medical or pharmaceutical use.

The proposed names are intended to provide indicative use of new substances based on manufacturer-supplied information, but the WHO does not endorse these statements or comment on the efficacy of the described actions. These names are provisional and will not be revised or included in the Cumulative Lists unless formally accepted.

Main Points

Proposed INN List 127 is being considered by WHO for inclusion in the Cumulative List of INNs.
The names are not recommendations for medical use.
The information about use and action is based on manufacturer data and is not verified by WHO.
The provisional nature of these names means they will not be included in the Cumulative Lists unless formally accepted.
Comments or objections can be submitted to the WHO INN Programme within four months of publication, i.e., by 21 November 2022 for List 127.
The publication date of List 127 is 22 July 2022.

Key Information

Proposed INN Examples

Proposed INN (Latin, English, French, Spanish)	Chemical Name or Description	Action and Use	Molecular Formula	CAS Registry Number	Graphic Formula
acidum deulinoleicum	(9Z,12Z)-octadeca-9,12-dienoic acid	Lipid peroxidation inhibitor, antioxidant	$\mathrm{C_{18}H_{30}O_2}$	31447-29-7	Image
acidum dimebuticum	2,2-dimethylbutanoic acid	Coenzyme A (CoA) ester precursor	$\mathrm{C_6H_{12}O_2}$	595-37-9	Image
acoltrémón	(1R,2S,5R)-N-(4-methoxyphenyl)-5-methyl-2-(propan-2-yl)cyclohexane-1-carboxamide	TRPM8 agonist, anti-inflammatory	$\mathrm{C_{18}H_{27}NO_2}$	68489-09-8	Image
alnugranogén	Recombinant, non-replicating AAV1 vector encoding human progranulin	Gene therapy for frontotemporal dementia	$\mathrm{C_{24}H_{21}N_3O_3}$	2389235-01-0	Image
anbalcabtagén	Autologous T lymphocytes transduced with a lentiviral vector encoding CAR and shRNA	Cell-based gene therapy for antineoplastic use	$\mathrm{C_{30}H_{32}N_6O_4}$	1448874-96-1	Image
anvatabart opadotine	Immunoglobulin G1-kappa, anti-ERBB2, conjugated with opadotin	Antineoplastic therapy	$\mathrm{C_{30}H_{32}N_6O_4}$	2607030-08-8	Image
anizatrectinib	N-[(3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl]-N' [4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl]urea	Tyrosine kinase inhibitor, antineoplastic	$\mathrm{C_{30}H_{32}N_6O_4}$	1448874-96-1	Image
ansornitinib	Methyl (3Z)-3-[4-[N-methyl-2-(4-methylpiperazin-1-yl)acetamido]anilinomethyldene)-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-6-carboxylate	Tyrosine kinase inhibitor	$\mathrm{C_{30}H_{32}N_6O_4}$	1448874-96-1	Image
anrikefon	1-[7-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-2,7-diazaspiro[3.5]nonan-2-yl]ethan-1-one	Kappa opioid receptor agonist, analgesic	$\mathrm{C_{23}H_{33}N_3O_2}$	2402772-93-2	Image
alvamémugène sulséparvovec	Recombinant, non-replicating AAV vector encoding methylmalonyl-CoA mutase	Gene therapy for methylmalonic acidemia	$\mathrm{C_{24}H_{21}N_3O_3}$	2389235-01-0	Image

Additional Notes

Feedback Period: Four months from the publication date (22 July 2022) to 21 November 2022.
Language Support: The names are provided in Latin, English, French, and Spanish.
Provisional Status: The names are not yet official and are not included in the Cumulative Lists unless formally accepted.
Structure: The document includes chemical names, action and use descriptions, molecular formulas, CAS registry numbers, and graphic formulas for each substance.
Scientific Detail: Some entries include structural details, molecular data, and gene therapy applications, such as the use of viral vectors and CAR-T cells for targeted treatment.